1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need

Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need", which provides insights into three therapeutic indications in gastrointestinal disorders in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the therapeutic indications of gastrointestinal disorders, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications.

Scope

- Disease overview and treatment usage patterns
- Market size and forecast for IBS, UC and CD in APAC market from 2012 to 2019
- Major marketed products for the indications types covered
- In-depth pipeline analysis for IBS, UC and CD
- Key drivers and restraints that have had and are expected to have a significant impact upon the market
- Key licensing and co-development agreements in the gastrointestinal therapeutics market

Reasons to buy

- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Table Of Contents

Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Gastrointestinal Therapeutics in Asia-Pacific Market - Introduction 11
2.1 Irritable Bowel Syndrome 11
2.1.1 Classification 11
2.1.2 Symptoms 11
2.1.3 Etiology 11
2.1.4 Pathophysiology 12
2.1.5 Diagnosis 12
2.1.6 Epidemiology 14
2.1.7 Prognosis 14
2.1.8 Treatment Options 14
2.2 Ulcerative Colitis 15
2.2.1 Classification 15
2.2.2 Symptoms 17
2.2.3 Etiology 17
2.2.4 Pathophysiology 17
2.2.5 Diagnosis 18
2.2.6 Epidemiology 19
2.2.7 Prognosis 19
2.2.8 Treatment Options 19
2.3 Crohn's Disease 21
2.3.1 Classification 21
2.3.2 Symptoms 22
2.3.3 Etiology 22
2.3.4 Pathophysiology 23
2.3.5 Diagnosis 23
2.3.6 Epidemiology 24
2.3.7 Prognosis 24
2.3.8 Treatment Options 25
3 Gastrointestinal Therapeutics in Asia-Pacific Market - Marketed Products (Global) 26
3.1 Irritable Bowel Syndrome 26
3.2 Ulcerative Colitis 26
3.3 Crohn's Disease 26
3.4 Key Marketed Products 27
3.4.1 Amitiza 27
3.4.2 Humira 28
3.4.3 Remicade 29
3.4.4 Simponi 30
3.4.5 Cimzia 31
3.4.6 Tysabri 32
4 Gastrointestinal Therapeutics in Asia-Pacific Market - Pipeline Analysis 34
4.1 Irritable Bowel Syndrome 34
4.1.1 Overall Pipeline 34
4.1.2 Pipeline Analysis by Molecule Type 36
4.1.3 Pipeline Analysis by Mechanism of Action 37
4.2 Ulcerative Colitis Pipeline 39
4.2.1 Overall Pipeline 39
4.2.2 Pipeline Analysis by Molecule Type 41
4.2.3 Pipeline Analysis by Mechanism of Action 42
4.3 Crohn's Disease Pipeline 44
4.3.1 Overall Pipeline 44
4.3.2 Pipeline Analysis by Molecule Type 46
4.3.3 Pipeline Analysis by Mechanism of Action 47
4.4 Promising Drug Candidates in the Pipeline 49
4.4.1 GSK-1605786 49
4.4.2 MLN0002 49
4.4.3 EMD-61753 49
5 Gastrointestinal Therapeutics in Asia-Pacific Market - Market Forecast to 2019 50
5.1 Asia-Pacific Markets 50
5.1.1 Treatment Usage Patterns 50
5.1.2 Annual Cost of Therapy 50
5.1.3 Market Size 50
5.2 Australia 52
5.2.1 Treatment Usage Patterns 52
5.2.2 Annual Cost of Therapy 52
5.2.3 Market Size 52
5.3 India 54
5.3.1 Treatment Usage Patterns 54
5.3.2 Annual Cost of Therapy 54
5.3.3 Market Size 54
5.4 China 56
5.4.1 Treatment Usage Patterns 56
5.4.2 Annual Cost of Therapy 56
5.4.3 Market Size 56
5.5 Japan 58
5.5.1 Treatment Usage Patterns 58
5.5.2 Annual Cost of Therapy 58
5.5.3 Market Size 58
5.6 Drivers and Barriers 60
5.6.1 Drivers 60
5.6.2 Barriers 60
6 Gastrointestinal Therapeutics in Asia-Pacific Market - Deals and Strategic Consolidations (Global) 61
6.1 Deals Analysis 61
6.2 Major Co-Development Deals 63
6.2.1 AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide 64
6.2.2 Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies 64
6.2.3 Galapagos and AbbVie Extend GLPG0634 Development Agreement to Include Crohn's Disease 64
6.3 Major Licensing Deals 65
6.3.1 AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3 Inhibitor Program 66
6.3.2 Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin 66
6.3.3 GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx 66
7 Gastrointestinal Therapeutics in Asia-Pacific Market - Appendix 67
7.1 Market Definitions 67
7.2 Abbreviations 67
7.3 Sources 69
7.4 All Pipeline Drugs by Phase 71
7.4.1 Discovery 71
7.4.2 Preclinical 71
7.4.3 IND/CTA-filed 72
7.4.4 Phase I 73
7.4.5 Phase II 74
7.4.6 Phase III 76
7.4.7 Pre-Registration 76
7.4.8 Undisclosed 77
7.5 Market Forecasts to 2019 77
7.5.1 Asia-Pacific Markets 77
7.5.2 Australia 78
7.5.3 India 79
7.5.4 China 80
7.5.5 Japan 81
7.6 Research Methodology 82
7.6.1 Coverage 82
7.6.2 Secondary Research 83
7.6.3 Primary Research 83
7.6.4 Therapeutic Landscape 83
7.6.5 Geographical Landscape 86
7.6.6 Pipeline Analysis 86
7.7 Expert Panel Validation 86
7.8 Contact Us 86
7.9 Disclaimer 861.1 List of Tables
Table 1: Gastrointestinal Therapeutics Market, Irritable Bowel Syndrome, Classification, 2009 11
Table 2: Gastrointestinal Therapeutics Market, Treatment Recommendations for Irritable Bowel Syndrome, 2009 15
Table 3: Gastrointestinal Therapeutics Market, Classification of Ulcerative Colitis, 2004 15
Table 4: Gastrointestinal Therapeutics Market, Diagnosis of Ulcerative Colitis, 2007 18
Table 5: Gastrointestinal Therapeutics Market, Difference Between Ulcerative Colitis and Crohn's Disease, 2007 18
Table 6: Gastrointestinal Therapeutics Market, Treatment Options of Ulcerative Colitis, 2011 21
Table 7: Gastrointestinal Therapeutics Market, Classification of Crohn's Disease, 2013 21
Table 8: Gastrointestinal Therapeutics Market, Percentage of Patients Affected by Symptoms of Crohn's Disease (%), 2012 22
Table 9: Gastrointestinal Therapeutics Market, Treatment Options for Crohn's Disease, 2009 25
Table 10: Gastrointestinal Therapeutics Market, Global, Pipeline (Discovery), 2013 71
Table 11: Gastrointestinal Therapeutics Market, Global, Pipeline (Preclinical), 2013 71
Table 12: Gastrointestinal Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 72
Table 13: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase I), 2013 73
Table 14: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase II), 2013 74
Table 15: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase III), 2013 76
Table 16: Gastrointestinal Therapeutics Market, Global, Pipeline (Pre-Registration), 2013 76
Table 17: Gastrointestinal Therapeutics Market, Global, Pipeline (Undisclosed), 2012 77
Table 18: Gastrointestinal Therapeutics Asia-Pacific Markets, Irritable Bowel Syndrome, Market Forecast, 2012-2019 77
Table 19: Gastrointestinal Therapeutics Market, Asia-Pacific Markets, Ulcerative Colitis, Market Forecast, 2012-2019 78
Table 20: Gastrointestinal Therapeutics Market, Asia-Pacific Markets, Crohn's Disease, Market Forecast, 2012-2019 78
Table 21: Gastrointestinal Therapeutics Market, Australia, Irritable Bowel Syndrome, Market Forecast, 2012-2019 78
Table 22: Gastrointestinal Therapeutics Market, Australia, Ulcerative Colitis, Market Forecast, 2012-2019 79
Table 23: Gastrointestinal Therapeutics Market, Australia, Crohn's Disease, Market Forecast, 2012-2019 79
Table 24: Gastrointestinal Therapeutics Market, India, Irritable Bowel Syndrome, Market Forecast, 2012-2019 79
Table 25: Gastrointestinal Therapeutics Market, India, Ulcerative Colitis, Market Forecast, 2012-2019 80
Table 26: Gastrointestinal Therapeutics Market, India, Crohn's Disease, Market Forecast, 2012-2019 80
Table 27: Gastrointestinal Therapeutics Market, China, Irritable Bowel Syndrome, Market Forecast, 2012-2019 80
Table 28: Gastrointestinal Therapeutics Market, China, Ulcerative Colitis, Market Forecast, 2012-2019 81
Table 29: Gastrointestinal Therapeutics Market, China, Crohn's Disease, Market Forecast, 2012-2019 81
Table 30: Gastrointestinal Therapeutics Market, Japan, Irritable Bowel Syndrome, Market Forecast, 2012-2019 81
Table 31: Gastrointestinal Therapeutics Market, Japan, Ulcerative Colitis, Market Forecast, 2012-2019 82
Table 32: Gastrointestinal Therapeutics Market, Japan, Crohn's Disease, Market Forecast, 2012-2019 821.2 List of Figures
Figure 1: Gastrointestinal Therapeutics Market, Treatment Algorithm of Ulcerative Colitis, 2007 20
Figure 2: Gastrointestinal Therapeutics Market, Global, Sales of Amitiza ($m), 2006-2012 27
Figure 3: Gastrointestinal Therapeutics Market, Global, Sales of Humira ($bn), 2006-2012 28
Figure 4: Gastrointestinal Therapeutics Market, Global, Sales of Remicade ($bn), 2006-2012 29
Figure 5: Gastrointestinal Therapeutics Market, Global, Sales of Simponi ($m), 2009-2012 30
Figure 6: Gastrointestinal Therapeutics Market, Global, Sales of Cimzia ($m), 2008-2012 31
Figure 7: Gastrointestinal Therapeutics Market, Global, Sales of Tysabri ($m), 2006-2012 32
Figure 8: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline, (%), 2013 35
Figure 9: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Molecule Type, 2013 36
Figure 10: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Mechanism of Action, 2012 38
Figure 11: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline, (%) 2013 40
Figure 12: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Molecule Type, 2013 41
Figure 13: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Mechanism of Action, 2013 43
Figure 14: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline, (%), 2013 45
Figure 15: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline by Molecule Type, 2013 46
Figure 16: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline by Mechanism of Action, 2013 48
Figure 17: Gastrointestinal Therapeutics Market, Asia-Pacific, Market Size, 2012-2019 51
Figure 18: Gastrointestinal Therapeutics Market, Australia, Market Size, 2012-2019 53
Figure 19: Gastrointestinal Therapeutics Market, India, Market Size, 2012-2019 55
Figure 20: Gastrointestinal Therapeutics Market, China, Market Size, 2012-2019 57
Figure 21: Gastrointestinal Therapeutics Market, Japan, Market Size, 2012-2019 59
Figure 22: Gastrointestinal Therapeutics Market, Global, Deals, 2006-2013 62
Figure 23: Gastrointestinal Therapeutics Market, Global, Co-Development Deals, 2006-2013 63
Figure 24: Gastrointestinal Therapeutics Market, Global, Licensing Deals, 2006-2013 65
Figure 25: GBI Research Market Forecasting Model 85

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.